EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

NCT03638167 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Central Nervous System Tumor, Pediatric
Glioma
Ependymoma
Medulloblastoma
Germ Cell Tumor
Atypical Teratoid/Rhabdoid Tumor
Primitive Neuroectodermal Tumor
Choroid Plexus Carcinoma
Pineoblastoma

Interventions

BIOLOGICAL: EGFR806-specific chimeric antigen receptor (CAR) T cell

Sponsor

Seattle Children's Hospital